Growth hormone-releasing peptide
GHRP-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin agonist that raised growth hormone in human studies; WADA lists it, and FDA lists it (injectable and nasal routes, section 503B) in category 2.
GHRP-2 after one dose: 50% at ~15 min, 25% at 30 min, 12.5% at 45 min.
Drawn from the half-life in the app's model, ~15 min. The model's figures
- Compound
- GHRP-2
- Symbol
- GR2
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 23
- Checked
- Last reviewed . Sources are listed below.
Overview
GHRP-2 is a growth hormone-releasing peptide, also called pralmorelin, KP-102 D and GPA 748.1 Pihoker and colleagues, Journal of Endocrinology, 1997, describe it as "a synthetic six amino acid peptide that is a potent GH secretagogue".2 A 2004 profile in Drugs in R&D says pralmorelin comes from a series of compounds developed by Polygen in Germany and Tulane University in the US.1
In Japan, a GHRP-2 test is used to evaluate growth hormone secretion, and Okano and colleagues, 2010, describe GHRP-2 as "intravenously used to diagnose growth hormone (GH) deficiency".3,4 The WADA 2026 Prohibited List names GHRP-2 (pralmorelin) in class S2, and FDA lists GHRP-2 for injectable and nasal routes in category 2 of bulk drug substances that may present significant safety risks.5,6
How it works
In people
Laferrère and colleagues, Journal of Clinical Endocrinology and Metabolism, 2005, describe GHRP-2 as "a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor".7 Pihoker and colleagues, 1995, describe GH-releasing peptides as synthetic peptides that, like GHRH, "act directly on pituitary somatotrophs to stimulate GH release".8
In 12 children with a robust response to intravenous GHRP-2, the response to GHRH plus GHRP-2 given together was synergistic.8 Bowers and colleagues, 2004, report that acute two-peptide synergy was 3-fold greater in young volunteers (n = 16) than in older ones (n = 17; P < 0.025).9
In 6 normal young adults aged 22 to 27 given intravenous GHRP-2 or hexarelin, Arvat and colleagues, Peptides, 1997, concluded that "The PRL-releasing activity of GHRPs is lower than that of TRH while their ACTH/cortisol-releasing activity is similar to that of hCRH".10 After 7 to 30 days of GHRP-2, GHRH or both in younger and older men and women, Bowers and Granda-Ayala, 1996, wrote that "Whether the GH response becomes desensitized during chronic administration depends in part on the dosage and frequency of administration".11
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~15 min
- Bioavailability
- 95%
- Typical dose
- 100–300 mcg/day
- Route
- SubQ
- Time to peak
- ~15 min
The app's figures are a half-life of about 15 minutes, a time to peak of about 15 minutes and a bioavailability of 95% by the subcutaneous route.
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~15 min (the app's figure) | Source figure: Pihoker and colleagues, 1998, gave 1 microgram/kg intravenously over 1 minute to ten prepubertal children with short stature and report a terminal half-life (t1/2 beta) of 0.55 ± 0.14 hours, about 33 minutes.12 |
| Clearance and volume of distribution | 0.66 ± 0.32 L/h x kg; 0.32 ± 0.14 L/kg | Same ten children and single intravenous dose; disposition best fit a biexponential function.12 |
| Time to peak | ~15 min (the app's figure) | Source figures: in the same children growth hormone peaked at 0.42 ± 0.16 hours after the dose, and in the adult test of Chihara and colleagues, 2007, serum GH peaked within 60 minutes of 100 micrograms intravenously. Both are peaks of growth hormone.12,13 |
| Bioavailability | 95% (the app's figure) | None of the studies and documents cited here reports a bioavailability figure for any route. |
| Routes reported | Intravenous, subcutaneous, intranasal, oral | The app lists the subcutaneous route. |
| Duration of GH effect | Relatively brief | Mericq and colleagues, 1998, report that the effect of subcutaneous injections "was relatively brief, with little effect upon GH secretion later in the night" in six children with GH deficiency.14 |
Reverter-Branchat and colleagues, Drug Testing and Analysis, 2021, detected GHRP-2 in dried blood spots up to 4 hours after a single intravenous dose of 100 micrograms.15
Nijland and colleagues, European Journal of Endocrinology, 1998, gave nine healthy subjects a daily subcutaneous injection of 100 micrograms GHRP-2 for 5 days.16 The chart below uses the app's half-life and time to peak, and its one interval, once a day, is the schedule of that study.
Level over 3 days
Level, as a share of the peak after one 100 mcg dose
As studied: every day16.
An illustration from a pharmacokinetic model using a half-life of 0.25 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Pihoker and colleagues, 199812 | Phase I pharmacokinetic study, single dose | 10 prepubertal children with short stature (9 boys, 1 girl; 7.7 ± 2.4 years) | 1 microgram/kg intravenously over 1 minute; sampling over 2 hours | Terminal half-life 0.55 ± 0.14 hours; peak GHRP-2 7.4 ± 3.8 ng/mL; peak GH 50.7 ± 17.2 ng/mL at 0.42 ± 0.16 hours. |
| Pihoker and colleagues, 19972 | Treatment study; no comparison group stated in the source text | 15 children with short stature, half GH deficient and half with idiopathic short stature; 6 followed for 18 to 24 months | Intranasal 5 to 15 micrograms/kg twice a day for 3 months, then three times a day; 6 months, and 18 to 24 months in 6 children | Height velocity rose from 3.7 ± 0.2 to 6.1 ± 0.3 cm/year at 6 months and was 6.0 ± 0.4 cm/year at 18 to 24 months; no significant changes in IGF-1, IGFBP-3 or acute GH responses; GH-binding protein rose from 439 ± 63 to 688 ± 48 pmol/l; the authors describe "a modest but significant increase in growth velocity". |
| Mericq and colleagues, 199814 | Stepwise dose study | 6 prepubertal children with GH deficiency and growth failure | Subcutaneous 0.3, 1.0 and 3.0 micrograms/kg/day in successive 2-month periods; then 3 micrograms/kg with 3 micrograms/kg GHRH | Overnight GH rose with dose; the effect was relatively brief; IGF-I and IGFBP-3 did not increase; growth velocity was higher during treatment than before and after; no side effects or toxicities observed. |
| Mericq and colleagues, 200317 | Treatment study of appetite and weight | 10 prepubertal children with GH deficiency, age 10.4 ± 2 years | Oral 900 micrograms/kg twice a day (b.i.d.) for 12 months | 7 of 10 reported a significant increase in appetite during the first 6 months; BMI SDS 0.21 ± 1.5 versus 0.25 ± 1.5, not statistically significant. |
| Nijland and colleagues, 199816 | Repeated-dose study | 9 healthy young men | 100 micrograms subcutaneously once daily for 5 days | Peak GH 83 ± 31, 59 ± 22 and 51 ± 13 micrograms/l on days 1, 3 and 5, a significant response attenuation (P < 0.01); mean IGF-I did not increase; osteocalcin rose from 3.2 ± 1.0 to 4.2 ± 0.4 micrograms/l (P < 0.01). |
| Laferrère and colleagues, 20057 | Infusion compared with saline, then a buffet meal | 7 lean, healthy men | 1 microgram/kg/h subcutaneously for 270 minutes | Meal intake was 35.9 ± 10.9% higher than on saline (136.0 ± 13.0 versus 101.3 ± 10.5 kJ/kg, p = 0.008). |
| Laferrère and colleagues, 200618 | Double-blind randomised infusion at three conditions | 19 healthy, weight-stable subjects (10 lean, 9 obese) | 0.1 or 1 microgram/kg per hour subcutaneously, or placebo, for 270 minutes | Food intake rose 10.2 ± 3.9% at low dose (p = 0.011) and 33.5 ± 5.8% at high dose (p = 0.000) against placebo; obesity status did not influence the effect on food intake. |
| Bowers and colleagues, 20049 | Acute and 30-day studies, saline comparison | Healthy older adults; 17 given the 30-day infusion | 1 microgram/kg/h by continuous subcutaneous infusion for 30 days | GH secretion rose more than 3-fold on day 1 and more than 1.8-fold on days 14 and 30 (each P < 0.001 versus saline); IGF-I rose to a stable plateau; IGFBP-3 and IGFBP-5 rose; safety screening tests remained normal. |
| Chihara and colleagues, 200713 | Diagnostic validation by the KP-102 Study Group | 77 healthy subjects and 58 patients with peak GH below 3 micrograms/l on the insulin tolerance test | 100 micrograms intravenously once; blood sampling for 2 hours | Peak GH 1.36 ± 2.60 micrograms/l in patients and 84.6 ± 60.9 in healthy subjects (P < 0.001); a 15 micrograms/l cut-off corresponded to 3 micrograms/l on the insulin tolerance test. |
| Van den Berghe and colleagues, 200219 | Randomised placebo-controlled study with four arms | 33 men with prolonged critical illness (placebo 7, GHRP-2 alone 9, GHRP-2 plus TRH 9, GHRP-2 plus TRH plus GnRH 8) | GHRP-2 1 microgram/kg/h by infusion for 5 days, alone or with TRH, or with TRH and pulsatile GnRH | GHRP-2 alone reactivated GH secretion and normalised serum IGF-I, IGFBP-3 and ALS (low at baseline); the authors report "superior endocrine and metabolic effects" with the TRH and GnRH combination than with GHRP-2 alone; ureagenesis fell with GHRP-2 plus TRH, with or without GnRH, but not with GHRP-2 alone; on day 5 serum lactate and white blood cell count were increased by GHRP-2 alone and with TRH. |
| Sigalos and colleagues, 201720 | Retrospective record review of a combination of GHRP-6, GHRP-2 and sermorelin, so the result is not GHRP-2 alone; no comparison group stated in the source text; the authors declared no conflicts of interest | 14 of 105 men on testosterone therapy, selected by strict inclusion criteria; mean age 33.2 years; 7 of the 14 received an aromatase inhibitor and/or tamoxifen, 3 before treatment and 4 during it | 100 micrograms of each three times daily; mean duration 134 days | Mean IGF-1 rose from 159.5 to 239.0 ng/mL (p < .0001); inhibition of estradiol production or estrogen receptor blockade resulted in smaller increases in IGF-1, the authors report. |
None of the source texts for the studies in the table states a funder. The 2003 report names the product as GPA-748 (Wyeth-Ayerst); no funder is stated. Several of these reports share an author with the peptide's development: Bowers CY of Tulane University Health Sciences Center is first author of the 2004 infusion report and a listed author of the 1995 Pihoker report cited here, the 1997 and 1998 Pihoker reports, both Mericq reports, both Laferrère reports and the 2002 Van den Berghe report in the table9. The Drugs in R&D profile names Dr Cyril Bowers of Tulane University as leading the group that synthesised the peptide series and says Tulane University was granted a US patent on a series of synthesised GH-releasing peptides1.
Deeper analysis: Pihoker and colleagues, 1998 (pharmacokinetics in children)
Pihoker, Kearns, French and Bowers published the study in the Journal of Clinical Endocrinology and Metabolism in 1998, with Pihoker's address given as the Department of Pediatrics, University of Washington, Seattle.12 The authors concluded that GHRP-2 "produced a predictable and significant (i.e. compared to pretreatment values) increase in plasma GH concentrations".12 The source text states no funder and lists no limitations of the study.
Deeper analysis: Chihara and colleagues, 2007 (diagnostic test in adults)
Chihara of the Kobe University Graduate School of Medicine and colleagues, writing as the KP-102 Study Group, reported the study in the European Journal of Endocrinology in 2007.13 The authors state that the insulin tolerance test is the first-line diagnostic test for adult GH deficiency and is "contraindicated in some patients due to severe adverse events", and that they validated GHRP-2 for the diagnosis.13 Serum GH peaked within 60 minutes in all subjects, responses were slightly lower in elderly subjects and those with adiposity without influencing the diagnosis, and repeated tests showed favourable reproducibility.13 The authors conclude that severe GH deficiency could be diagnosed with high reliability using a 15 micrograms/l cut-off, or 9 micrograms/l when GH is calibrated with the recombinant World Health Organization 98/574 standard.13 The group's name uses the code KP-102; the Drugs in R&D profile lists KP-102 D among pralmorelin's names and says Kaken retains rights to pralmorelin in Japan.1 The source text of the study states no funder and lists no limitations.
Deeper analysis: Laferrère and colleagues, 2005 and 2006 (food intake)
In the 2005 study, 7 lean, healthy men received a subcutaneous infusion of GHRP-2 at 1 microgram/kg/h or saline for 270 minutes and then an ad libitum buffet meal.7 The 2006 study added a low dose and 9 obese subjects, and obesity status did not influence the effect on food intake.18 Bowers CY is a listed author of both reports, and neither source text states a funder or limitations.7,18
Deeper analysis: Bowers and colleagues, 2004 (30-day infusion)
Bowers, Granda, Mohan, Kuipers, Baylink and Veldhuis, with Bowers at Tulane University Health Sciences Center, reported acute, 24-hour and 30-day studies in healthy older adults in the Journal of Clinical Endocrinology and Metabolism in 2004.9 The 30-day infusion in 17 subjects held IGF-I at a stable plateau and raised IGFBP-3 and IGFBP-5, and the authors conclude that 30-day stimulation with GHRP-2 "sustains a physiologically activated somatotropic axis".9 The source text states no funder and lists no limitations.
Doses reported in studies
The app's typical dose is 100 to 300 mcg/day by the subcutaneous route. Nijland and colleagues gave a fixed 100 micrograms subcutaneously once daily for 5 days, while Mericq and colleagues, 1998, dosed by body weight, at 0.3 to 3 micrograms/kg/day, and the infusion studies used 1 microgram/kg/h (0.1 and 1 in Laferrère and colleagues, 2006).16,14,18
| Source | Route | Dose | Frequency and length |
|---|---|---|---|
| Chihara and colleagues, 200713 | Intravenous | 100 micrograms | Single test dose; sampling for 2 hours |
| Asakura and colleagues, 201021 | Intravenous | 2 micrograms/kg | Single test dose |
| Nijland and colleagues, 199816 | Subcutaneous injection | 100 micrograms | Once daily for 5 days |
| Mericq and colleagues, 199814 | Subcutaneous | 0.3, 1.0 and 3.0 micrograms/kg/day | Successive 2-month periods, then a fourth 2-month period with GHRH |
| Laferrère and colleagues, 20057 | Subcutaneous infusion | 1 microgram/kg/h | 270 minutes |
| Laferrère and colleagues, 200618 | Subcutaneous infusion | 0.1 and 1 microgram/kg per hour | 270 minutes, three visits |
| Bowers and colleagues, 20049 | Continuous subcutaneous infusion | 1 microgram/kg/h | 30 days |
| Van den Berghe and colleagues, 200219 | Infusion | 1 microgram/kg/h, alone, with TRH, or with TRH and pulsatile GnRH | 5 days |
| Pihoker and colleagues, 19972 | Intranasal | 5 to 15 micrograms/kg | Twice a day for 3 months, then three times a day; 6 months in 15 children, 18 to 24 months in 6 |
| Mericq and colleagues, 200317 | Oral | 900 micrograms/kg | Twice a day for 12 months |
| Sigalos and colleagues, 2017 (with GHRP-6 and sermorelin)20 | Not stated in the source text | 100 micrograms of each | Three times daily; mean duration 134 days |
Side effects reported
Mericq and colleagues, 1998, report "There were no side effects or toxicities observed" in 6 children given subcutaneous GHRP-2 in successive 2-month periods.14 Pihoker and colleagues reported that intranasal GHRP-2 was well tolerated in 1995 and in 1997.8,2 Bowers and colleagues, 2004, report that safety screening tests remained normal during the 30-day infusion in older adults.9
In 10 children with GH deficiency given 900 micrograms/kg orally twice a day for 12 months, 7 reported a significant increase in appetite during the first 6 months, and the authors describe "a transient stimulatory effect on appetite" without a statistically significant change in BMI.17
In men with prolonged critical illness, serum lactate and white blood cell count were increased on day 5 by GHRP-2 infused alone and in combination with TRH, Van den Berghe and colleagues, 2002, report.19 Arvat and colleagues, 1997, report that GHRP-2 and hexarelin were not fully specific for GH, since prolactin, ACTH and cortisol also responded.10
A 2018 review of growth hormone secretagogues, a class that a 2017 paper by the same first two authors says includes GHRP-2 and GHRP-6, states: "Available studies indicate that GHSs are well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity".22,20 FDA's category 2 entry for GHRP-2 states that compounded GHRP-2 for injectable and nasal administration "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities".6 The entry adds that FDA is aware of reports of serious adverse events in patients who received GHRP-2, "including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis, though causality has not been established".6
Bloodwork and markers
The app lists IGF-1, blood glucose and insulin as markers for GHRP-2. IGF-I results differed by study: IGF-I rose to a stable plateau across a 30-day infusion in older adults, did not increase after 5 days of daily injections in healthy young men, and did not increase in the 6-child stepwise study or the intranasal children's study.9,16,14,2 In men with prolonged critical illness and low baseline IGF-I (9 given GHRP-2 alone), infused GHRP-2 alone normalised serum IGF-I, IGFBP-3 and the acid-labile subunit (ALS), Van den Berghe and colleagues, 2002, report.19
In diagnostic use, peak GH after intravenous GHRP-2 is compared with a cut-off: Chihara and colleagues, 2007, give 15 micrograms/l, or 9 micrograms/l when GH is calibrated with the recombinant World Health Organization 98/574 standard.13 Soga and colleagues, 2020, state that the cut-off for peak GH during a GHRP-2 test for severe adult GH deficiency in Japan is 9 ng/mL or below, and the source text states no calibration.3
Regulatory and anti-doping status
The WADA Prohibited List 2026, in effect from 1 January 2026, names "GHRP-2 (pralmorelin)" under S2.2.4 among GH-releasing peptides.5 Class S2 is prohibited at all times, in and out of competition, and "All prohibited substances in this class are non-Specified Substances".5
FDA lists "Growth hormone releasing peptide-2 (GHRP-2) (for injectable and nasal routes of administration)" as a section 503B entry in category 2 of the bulk substances nominated under sections 503A or 503B, added on 29 September 2023.6 FDA's page states that bulk drug substances that may present significant safety risks "have been placed in category 2 under the interim policies" and was current as of 22 April 2026.6
Kinoshita and colleagues, 2013, write that "the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan" to the insulin tolerance test for adult GH deficiency.23 A 2004 Drugs in R&D profile reported pralmorelin as KP-102 D awaiting approval in Japan as a diagnostic agent for hypothalamo-pituitary function, with a launch planned for 2004, and said US phase II development with Wyeth appeared to have been discontinued.1
What is not known
An elimination half-life of GHRP-2 is reported in one cited study (ten children, single intravenous dose, 0.55 ± 0.14 hours), and none reports a bioavailability figure.12 The longest treatment in the cited studies is intranasal GHRP-2 for 18 to 24 months in 6 children (Pihoker and colleagues, 1997; 15 children took part for 6 months), then oral treatment for 12 months in 10 children and a 30-day infusion in 17 older adults.2,17,9 Sigalos and Pastuszak, 2018, write for growth hormone secretagogues as a class that "few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs" and that the safety of long-term use, "including evaluation of cancer incidence and mortality, is needed".22
Mericq and colleagues, 1998, wrote that "Formulations or routes of administration that allow for a longer duration of action will likely be needed to use GHRP-2 in therapy".14 The combined results of Van den Berghe and colleagues, 2002, and Sigalos and colleagues, 2017, involve GHRP-2 given with TRH, GnRH, GHRP-6 or sermorelin, so they are not taken as results of GHRP-2 alone.19,20 A ClinicalTrials.gov search on 16 November 2026 for "GHRP-2" and for "pralmorelin" returned no studies. No product label for GHRP-2 from PMDA, FDA, EMA or TGA is among the cited sources, so approved indications, strengths and storage are not stated here.
Frequently asked questions
Sources in this part
- 1Pralmorelin: GHRP 2, 2004
- 2Pihoker et al., 1997
- 3Soga et al., 2020
- 5World Anti-Doping Agency, 2026
- 6US Food and Drug Administration, 2026
- 7Laferrère B, 2005
- 9Bowers et al., 2004
- 12Pihoker et al., 1998
- 13Chihara et al., 2007
- 14Mericq et al., 1998
- 15Reverter-Branchat et al., 2021
- 16Nijland et al., 1998
- 17Mericq et al., 2003
- 18Laferrère B, 2006
- 19Van den Berghe G, 2002
What is GHRP-2?
What is the half-life of GHRP-2?
The app lists a half-life of about 15 minutes. In ten children given 1 microgram/kg intravenously, Pihoker and colleagues, 1998, report a terminal half-life of 0.55 ± 0.14 hours, about 33 minutes.12
Is GHRP-2 banned by WADA?
What is the FDA's position on GHRP-2?
Does GHRP-2 increase appetite?
In 7 lean, healthy men, a subcutaneous infusion of GHRP-2 at 1 microgram/kg/h raised intake at a buffet meal by 35.9 ± 10.9% compared with saline (Laferrère and colleagues, 2005).7 In 19 lean and obese subjects, intake rose 10.2 ± 3.9% at 0.1 and 33.5 ± 5.8% at 1 microgram/kg per hour (Laferrère and colleagues, 2006).18 In 10 children with GH deficiency given 900 micrograms/kg orally twice a day for 12 months, 7 reported a significant increase in appetite during the first 6 months, BMI SDS did not change significantly, and the authors describe "a transient stimulatory effect on appetite" (Mericq and colleagues, 2003).17 The adult intake results come from 270-minute infusions, one per study visit.7,18
Does GHRP-2 raise IGF-1?
Results differ by study: IGF-I rose to a stable plateau during a 30-day subcutaneous infusion in older adults (Bowers and colleagues, 2004).9 It did not increase after 5 days of daily 100 microgram injections in healthy young men (Nijland and colleagues, 1998), nor in 6 children given stepwise subcutaneous doses (Mericq and colleagues, 1998).16,14 In men with prolonged critical illness and low baseline IGF-I, GHRP-2 infused alone normalised serum IGF-I, IGFBP-3 and ALS (Van den Berghe and colleagues, 2002).19
What is GHRP-2 used for in Japan?
How long can GHRP-2 be detected after a dose?
In an administration study with a single intravenous dose of 100 micrograms, GHRP-2 was detected in dried blood spots up to 4 hours after injection (Reverter-Branchat and colleagues, 2021).15
Guides, tools and comparisons
References
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D 2004. PMID 15230633
- Pihoker C, Badger TM, Reynolds GA, Bowers CY. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 1997. PMID 9390009
- Soga A, Fukuda I, Kobayashi S, Tahara S, Morita A, Sugihara H. Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas. Endocr J 2020. PMID 31776295
- Okano M, Sato M, Ikekita A, Kageyama S. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2010. PMID 20552695
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In effect 1 January 2026. WADA Prohibited List 2026
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2 of the bulk substances nominated under sections 503A or 503B). Page current as of 22 April 2026. FDA category 2 page
- Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005. PMID 15699539
- Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab 1995. PMID 7559885
- Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab 2004. PMID 15126555
- Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997. PMID 9285939
- Bowers CY, Granda-Ayala R. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab 1996. PMID 8887169
- Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab 1998. PMID 9543135
- Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y; KP-102 Study Group. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol 2007. PMID 17609397
- Mericq V, Cassorla F, Salazar T, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998. PMID 9661608
- Reverter-Branchat G, Segura J, Pozo OJ. On the road of dried blood spot sampling for antidoping tests: detection of GHRP-2 abuse. Drug Test Anal 2021. PMID 33197153
- Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. Eur J Endocrinol 1998. PMID 9820615
- Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003. PMID 14513874
- Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring) 2006. PMID 16861611
- Van den Berghe G, Baxter RC, Weekers F, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002. PMID 12030918
- Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health 2017. PMID 28830317
- Asakura Y, Toyota Y, Muroya K, Adachi M. Growth hormone response to GH-releasing peptide-2 in children. J Pediatr Endocrinol Metab 2010. PMID 20662346
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018. PMID 28400207
- Kinoshita Y, Tominaga A, Usui S, et al. The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison. Endocr J 2013. PMID 23079545